Bilateral upper extremity severe ecchymosis in a patient on alirocumab, rivaroxaban, and clopidogrel therapy

Parth R Shah, Charles J Glueck,∗ Vybhav Jetty

Jewish-Mercy Cholesterol and Metabolism Center, USA

Received: January 13, 2016 Accepted: February 28, 2016 Online Published: March 4, 2016 DOI: 10.5430/crim.v3n2p11 URL: http://dx.doi.org/10.5430/crim.v3n2p11

ABSTRACT

The PCSK9 inhibitors, alirocumab and evolocumab, are a new class of powerful LDL cholesterol lowering agents which allow previously unattainable lowering of LDL cholesterol (LDLC). Once past the necessarily restrictive confines of placebo-controlled clinical trials, in current medical practice, some patients with concomitant thromboembolism and arterial disease may also be taking potent anticoagulants and/or anti-platelet agents in addition to PCSK9 inhibitors. There are currently no reports on drug interactions and no warnings when alirocumab or evolocumab are used in conjunction with anticoagulants and/or anti-platelet therapy. Here, we present a case of patient with exceptional LDLC lowering (LDLC < 4 mg/dl) on alirocumab 150 mg/ml every 2 weeks and concomitant anti-platelet (clopidogrel 75 mg/day) and anti-coagulation therapy (rivaroxaban 10 mg/day) because of recurrent non-cardiogenic amaurosis fugax, and transient ischemic attacks, and ischemic stroke associated with heterozygosity for the G20210A prothrombin gene mutation. On this regimen, the patient developed gradually spreading intensive skin ecchymosis and bleeding on both arms. This resolved after stopping alirocumab, clopidogrel, and rivaroxaban, and did not reappear when clopidogrel and rivaroxaban were restarted without alirocumab.

Key Words: PCSK9 inhibitors, Alirocumab, Cholesterol, Clopidogrel, Rivoraxaban, Anti-platelet, Anti-coagulation

1. INTRODUCTION

LDL cholesterol (LDLC) lowering beyond the lowest levels achievable with maximal diet-drug regimens has been revolutionized by PCSK9 inhibitors, which are indicated as an adjunct to diet-maximally tolerated cholesterol lowering drug therapy in heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia, and/or clinical atherosclerotic cardiovascular disease (CVD) where LDLC lowering is insufficient despite maximal tolerated therapy. Alirocumab ODYSSEY Phase III studies demonstrated that the mean percentage change in calculated LDL cholesterol level from baseline to week 24 was 61% (alirocumab) vs. 0.8% (placebo), p < .001.[1] In 2,461 patients treated with alirocumab, 796 (32%) had two consecutive LDLC levels < 25 mg/dl while 288 (12%) had two consecutive LDLC levels < 15 mg/dl.[2] Furthermore, in the OSLER-1 and OSLER-2 phase III trials, evolocumab reduced LDL cholesterol levels by 61% at 12-week on-treatment median.[3] In a pool of 2,651 evolocumab-receiving patients, 1,609 (61%) had at least one LDLC < 25 mg/dl.[4]

Compared to the placebo, there were minimal adverse reactions to the PCSK9 inhibitors with differences between placebo vs. PCSK9 inhibitor group consistently <
Injection site reactions occur in approximately 7.2% (alirocumab) vs. 5.1% (placebo) of enrolled subjects in the studies, and allergic reactions have been reported to be 8.6% (alirocumab) vs. 7.8% (placebo). Injection site reactions occur in approximately 3.2% (evolocumab) vs. 3.0% (placebo) subjects, while allergic reactions were 5.1% (evolocumab) vs. 4.6% (placebo). There are no drug to drug interaction data or warnings when using alirocumab or evolocumab in conjunction with anticoagulants and/or anti-platelet therapy.

2. CASE REPORT
The patient, a 70-year-old non-smoking Caucasian male, was referred to our center because of non-cardiogenic recurrent amaurosis fugax, and transient ischemic attacks (TIAs) and ischemic strokes in the presence of normal carotid and coronary artery imaging, and in the absence of atrial fibrillation. He was found to be heterozygous for the G20210A prothrombin gene mutation, which is known to be associated with retinal artery thrombotic occlusion, amaurosis fugax, and ischemic stroke, as well as, more commonly, venous thrombosis. Due to increased frequency of amaurosis fugax episodes and ischemic stroke-TIAs, he was initially anticoagulated with enoxaparin (1 mg/kg/twice per day), with a sharp reduction in the frequency of amaurosis fugax attacks, and non-recurrence of TIAs and ischemic strokes. He was subsequently anticoagulated with rivaroxaban (10 mg/day) for 3 years. However, after reoccurrence of TIAs despite rivaroxaban, clopidogrel 75 mg/day was added, and continued uneventfully without skin bruising or bleeding for 1 year.

Our initial evaluation revealed heterozygous familial hypercholesterolemia as per Simon Broome’s criteria. Despite a low cholesterol and low saturated fat diet plus rosuvastatin 40 mg and ezetimibe 10 mg, the lowest LDLC achieved was 144 mg/dl. Given the patient’s history of TIAs and ischemic stroke, our target was LDLC < 70 mg/dl. Unable to attain LDLC < 70 mg/dl despite maximally tolerated cholesterol lowering therapy, he met FDA indications for PCSK9 therapy, and alirocumab 150 mg/ml was started subcutaneously every two weeks to achieve a LDLC target < 70 mg/dl.

After being on alirocumab 150 mg every 2 weeks for 6 weeks (3 doses), the patient presented with a diffuse ecchymotic-hemorrhagic bruising on both arms which started as an area of central clearing followed by blood spreading out in a circular fashion. Blood oozed out from the ecchymotic sites intermittently, but there was no pain or tenderness (see Figure 1). Normal findings included platelet count 175 × 10^3, hemoglobin 14.7 g/dl, and hematocrit 44.7%; there was no evidence of systemic bleeding. Factor VIII was not measured at the time of ecchymosis to rule out acquired hemophilia, but had been normal (110%) before any anticoagulant or alirocumab therapy. Previous to development of the ecchymotic-bruising, four weeks after starting alirocumab, total cholesterol had fallen from 211 to 87 mg/dl, and LDLC from 144 to < 4 mg/dl. All other laboratory tests including complete blood count with differential and comprehensive metabolic panel were normal after four weeks on alirocumab.

Figure 1. Ecchymosis, bruising, and bleeding into the skin after 6 weeks of alirocumab with concomitant rivaroxaban and clopidogrel therapy

At week seven, after three doses of alirocumab and appearance of the ecchymosis and bruising and bleeding into the skin, we discontinued clopidogrel, rivaroxaban, and Alirocumab. Within 1 week, the ecchymosis-bruising had begun to fade and recede. Because the frequency of symptoms of amaurosis fugax accelerated markedly during the time period off anticoagulants, clopidogrel and rivaroxaban were uneventfully restarted, without recurrence of the hemorrhagic ecchymosis in the skin. After 6 weeks back on clopidogrel
and rivaroxaban, there was no ecchymosis and no bruising and the forearm skin regained the same appearance as prior to alirocumab therapy (see Figure 2).

![Figure 2. Six weeks after stopping alirocumab and restarting rivaroxaban and clopidogrel therapy](image)

### 3. DISCUSSION

Could the alirocumab-driven reduction of LDLC to < 4 mg/dl in the presence of concurrent rivaroxaban and clopidogrel therapy have led to the extensive ecchymosis in the skin which resolved quickly (6 weeks) after alirocumab was discontinued? In abetalipoproteinemia, a condition in which LDLC is close to zero, platelets have a decreased response to aggregating stimuli\(^{[18,19]}\) and the low levels of LDLC are thought to affect the clearance rate of plasma platelet-activating factor acetylhydrolase, thus reducing platelet aggregation.\(^{[20]}\)

As shown by the controlled clinical drug trial data for alirocumab and evolocumab, patients are now frequently able to attain LDLC < 25 mg/dl.\(^{[2-4]}\) In safety data from the JUPITER trial involving rosuvastatin 20 mg, when patients attained LDLC < 30 mg/dl, there was an increased physician reporting of hematuria, without statistically significant increased risk for hemorrhagic stroke.\(^{[14,21]}\) When LDLC is lowered in patients with normal high density lipoprotein cholesterol (HDLC), there is a significant decrease in platelet activation.\(^{[22]}\) Previous studies with atorvastatin 20 mg/day therapy revealed that it normalized platelet hyperfunction and significantly reduced GPIIb/IIIa response to ADP.\(^{[23]}\) When atorvastatin 20 mg/day was given to patients with high LDLC and low HDLC vs. high LDLC and normal HDLC, platelet activation was not significantly decreased in the high LDLC and low HDLC versus high LDLC and normal HDLC group.\(^{[22]}\)

Increased LDL cholesterol is associated with increased platelet aggregation.\(^{[22-25]}\) Hypercholesterolemic patients have been shown to have high percentage of GPIIb/IIIa-phosphatidylserine, and CD62p positive platelets, increased plasma viscosity, and high erythrocyte aggregation index compared to controls.\(^{[22-24]}\) Furthermore, in hypercholesterolemic individuals, platelets generate oxidized-LDL which leads to more platelet aggregation.\(^{[25]}\)

We cannot completely rule out the unlikely possibility of drug induced transient acquired hemophilia leading to the ecchymosis and bruising in the skin. Acquired hemophilia, affecting factor VIII, is very rare and occurs in about one in a million people, with women affected 55% of the time. Drugs known to be associated with acquired hemophilia include penicillin, sulfonamides, chloramphenicol, diphenylhydantoin, fludarabine, and interferon-\(\alpha\), none of which had been given to our patient.\(^{[26-28]}\)

For patients with heterozygous familial hypercholesterolemia, and/or cardiovascular disease with suboptimal LDLC lowering despite maximal tolerated conventional diet-drug therapy,\(^{[1,3]}\) PCSK9 therapy provides a very effective new therapeutic avenue. In those patients receiving PCSK9 therapy, who, as in the current case, require concurrent antiplatelet and factor Xa inhibition, further studies need to be done to determine whether extraordinary LDLC lowering mediated by PCSK9 therapy may affect the platelet function, thus facilitating development of ecchymotic bruising-bleeding into the skin when accompanied by clopidogrel and/or rivaroxaban.

**CONFLICTS OF INTEREST DISCLOSURE**

The authors have declared no conflicts of interest.

### REFERENCES


